Tardive dyskinesia and anticholinergic drugs

Am J Psychiatry. 1983 Feb;140(2):200-2. doi: 10.1176/ajp.140.2.200.

Abstract

The evidence from the literature does not support the notion that psychotropic drugs with central anticholinergic properties (antiparkinsonian drugs, neuroleptics, antidepressants) constitute a risk factor in tardive dyskinesia. Antiparkinsonian drugs tend to produce reversible increases in the severity of dyskinetic movements and can be used as pharmacological probes in the assessment of neuroleptic-induced movement disorders.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Acute Disease
  • Antidepressive Agents / adverse effects
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / pharmacology
  • Drug Interactions
  • Dyskinesia, Drug-Induced / drug therapy
  • Dyskinesia, Drug-Induced / etiology*
  • Humans
  • Parasympatholytics / adverse effects*
  • Risk

Substances

  • Antidepressive Agents
  • Antiparkinson Agents
  • Antipsychotic Agents
  • Parasympatholytics